Clinical Trials Browser

Unknown × Interventional × HER2-positive Breast Cancer × Clear all

NCT05985187 2023-08-14

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Phase 3 Unknown

HER2-positive Breast Cancer

NCT05945368 2023-07-14

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

Phase 2 Unknown

HER2-positive Breast Cancer

NCT05429294 2022-06-23

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Phase 2 Unknown

HER2-positive Breast Cancer

NCT05334810 2022-04-19

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer

NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Phase 2/3 Unknown

HER2-positive Breast Cancer

NCT05154396 2021-12-13

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer

NCT03238495 2021-12-07

HERMET

Phase 2 Unknown

HER2-positive Breast Cancer

NCT03655353 2021-09-29

Affibody-3

Phase NA Unknown

HER2-positive Breast Cancer

NCT04170595 2021-03-03

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

Phase 1/2 Unknown

HER2-positive Breast Cancer

NCT03933319 2020-07-08

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer

NCT04034823 2019-07-26

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer

NCT03919253 2019-04-18

Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study

Phase 2 Unknown

HER2-positive Breast Cancer

NCT03881878 2019-03-21

TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

Phase 1/2 Unknown

HER2-positive Breast Cancer

NCT03847818 2019-03-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

Phase NA Unknown

HER2-positive Breast Cancer

NCT03684863 2018-09-26

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Phase 2 Unknown

HER2-positive Breast Cancer